Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer-a dose-response meta-analysis

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 584-591

  Discacciati, A ^a   Orsini, N ^a   Wolk, A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Coffee; Dose response meta analysis; Epidemiology; Prostate cancer

Indexed keywords

ADVANCED CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; COFFEE; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; FATALITY; GLEASON SCORE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS;

COFFEE; DOSE-RESPONSE META-ANALYSIS; EPIDEMIOLOGY; PROSTATE CANCER;

COFFEE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; OXIDATIVE STRESS; PROSTATIC NEOPLASMS;

EID: 84896691708     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt420     Document Type: Review

References (50)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69-90.
2. Imatoh T, Tanihara S, Miyazaki M et al. Coffee consumption but not green tea consumption is associated with adiponectin levels in japanese males. Eur J Nutr 2011; 50(4): 279-284.
3. Kempf K, Herder C, Erlund I et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 2010; 91(4): 950-957.
4. Wedick NM, Brennan AM, Sun Q et al. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J 2011; 10: 93.
5. Williams CJ, Fargnoli JL, Hwang JJ et al. Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care 2008; 31(3): 504-507.
6. Nakajima A, Endo H, Yoneda K et al. Molecular mechanisms linking adiponectin receptor signalling and cancer. Open Obes J 2010; 2: 43-49.
7. Lu J-P, Hou ZF, Duivenvoorden WC et al. Adiponectin inhibits oxidative stress in human prostate carcinoma cells. Prostate Cancer Prostatic Dis 2012; 15(1): 28-35.
8. Rautiainen S, Levitan EB, Mittleman MA et al. Total antioxidant capacity of diet and risk of heart failure: a population-based prospective cohort of women. Am J Med 2013; 126(6): 494-500.
9. Rautiainen S, Levitan EB, Orsini N et al. Total antioxidant capacity from diet and risk of myocardial infarction: a prospective cohort of women. Am J Med 2012; 125(10): 974-980.
10. Svartberg J, Midtby M, Bønaa KH et al. The associations of age, lifestyle factors and chronic disease with testosterone in men: the Tromsø Study. Eur J Endocrinol Eur Fed Endocr Soc 2003; 149(2): 145-152.
11. Yasui T, Tomita J, Miyatani Y et al. Associations of adiponectin with sex hormonebinding globulin levels in aging male and female populations. Clin Chim Acta Int J Clin Chem 2007; 386(1-2): 69-75.
12. Bardia A, Platz EA, Yegnasubramanian S et al. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. Curr Opin Pharmacol 2009; 9(4): 419-426.
13. Price AJ, Allen NE, Appleby PN et al. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2012; 21(9): 1531-1541.
14. Roddam AW, Allen NE, Appleby P et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149(7): 461-471, W83.-W88.
15. Roddam AW, Allen NE, Appleby P et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100(3): 170-183.
16. Schröder FH, van Weerden WM. Prostate cancer-chemoprevention. Eur J Cancer 2009; 45(Suppl. 1): 355-359.
17. Bosire C, Stampfer MJ, Subar AF et al. Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control 2013; 24(8): 1527-1534.
18. Discacciati A, Orsini N, Andersson S-O et al. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. Ann Oncol 2013; 24(7): 1912-1918.
19. Shafique K, McLoone P, Qureshi K et al. Coffee consumption and prostate cancer risk: further evidence for inverse relationship. Nutr J 2012; 11: 42.
20. Wilson KM, Kasperzyk JL, Rider JR et al. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 2011; 103(11): 876-884.
21. Wilson KM, Bälter K, Möller E et al. Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study. Cancer Causes Control 2013; 24(8): 1575-1581.
22. Park C-H, Myung S-K, Kim T-Y et al. Coffee consumption and risk of prostate cancer: a meta-analysis of epidemiological studies. BJU Int 2010; 106(6): 762-769.
23. Yu X, Bao Z, Zou J et al. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer 2011; 11: 96.
24. Gong Z, Agalliu I, Lin DW et al. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control 2008; 19(1): 25-31.
25. Huncharek M, Haddock KS, Reid R et al. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010; 100(4): 693-701.
26. Rohrmann S, Linseisen J, Allen N et al. Smoking and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2013; 108(3): 708-714.
27. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135(11): 1301-1309.
28. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation from summarized dose-response data. Stata J 2006; 6: 40-57.
29. Orsini N, Li R, Wolk A et al. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol 2012; 175(1): 66-73.
30. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558.
31. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
32. Polesel J, Zucchetto A, Talamini R et al. Re: coffee consumption and prostate cancer risk and progression in the health professional follow-up study. J Natl Cancer Inst 2012; 104(21): 1684-1686; author reply 1686.
33. Geybels MS, Neuhouser ML, Stanford JL. Associations of tea and coffee consumption with prostate cancer risk. Cancer Causes Control 2013; 24(5): 941-948.
34. Li Q, Kakizaki M, Sugawara Y et al. Coffee consumption and the risk of prostate cancer: the ohsaki cohort study. Br J Cancer 2013; 108(11): 2381-2389.
35. Stark JR, Perner S, Stampfer MJ et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009; 27(21): 3459-3464.
36. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23(7): 1665-1671.
37. Xu H, Jiang H, Ding G et al. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract 2013; 99(3): 241-249.
38. Hsing AW, McLaughlin JK, Schuman LM et al. Diet, tobacco use, and fatal prostate cancer: results from the lutheran brotherhood cohort study. Cancer Res 1990; 50 (21): 6836-6840.
39. Phillips RL, Snowdon DA. Association of meat and coffee use with cancers of the large bowel, breast, and prostate among Seventh-Day Adventists: preliminary results. Cancer Res 1983; 43(Suppl. 5): 2403s-2408s.
40. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010; 91(1): 258S-261S.
41. Izadi V, Farabad E, Azadbakht L. Serum adiponectin level and different kinds of cancer: a review of recent evidence. ISRN Oncol 2012; 2012: 982769.
42. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41(18): 2887-2895.
43. Ma J, Li H, Giovannucci E et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9(11): 1039-1047.
44. Hsing AW, Chua S, Jr, Gao YT et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001; 93(10): 783-789.
45. Lehrer S, Diamond EJ, Stagger S et al. Increased serum insulin associated with increased risk of prostate cancer recurrence. Prostate 2002; 50(1): 1-3.
46. Ferrini RL, Barrett-Connor E. Caffeine intake and endogenous sex steroid levels in postmenopausal women. The Rancho Bernardo Study. Am J Epidemiol 1996; 144 (7): 642-644.
47. Kotsopoulos J, Eliassen AH, Missmer SA et al. Relationship between caffeine intake and plasma sex hormone concentrations in premenopausal and postmenopausal women. Cancer 2009; 115(12): 2765-2774.
48. London S, Willett W, Longcope C et al. Alcohol and other dietary factors in relation to serum hormone concentrations in women at climacteric. Am J Clin Nutr 1991; 53(1): 166-171.
49. Nagata C, Kabuto M, Shimizu H. Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. Nutr Cancer 1998; 30(1): 21-24.
50. Thapa D, Ghosh R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities. Biochem Pharmacol 2012; 83(10): 1319-1330.